Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment
To evaluate the efficacy (ORR) and safety of anti PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy in the treatment of advanced NSCLC progressed after EGFR-TKI treatment and to provide new treatment methods for EGFR-TKI resistant patients.
NSCLC|EGFR Gene Mutation
OTHER: neo-antigen vaccine
ORR, Exploration of the efficacy of anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy in the treatment of advanced NSCLC with previous EGFR-TKI treatment failure, three years
PFS, Observe and evaluate the progression free survival (PFS), overal survival(OS) of advanced NSCLC patients who have failed previous EGFR-TKI treatment with anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy;, three years|OS, Observe and evaluate the overal survival(OS) of advanced NSCLC patients who have failed previous EGFR-TKI treatment with anti-PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy;, three years
To evaluate the efficacy (ORR) and safety of anti PD-1 monoclonal antibody combined with neoantigen peptide vaccine and chemotherapy in the treatment of advanced NSCLC progressed after EGFR-TKI treatment and to provide new treatment methods for EGFR-TKI resistant patients.